Lee's Pharmaceutical Holdings Limited (0950) AI Stock Analysis

• Market Cap: HK$783.15M
• Dividend Yield: 2.92%
• Average Volume (3M): 5.40M
• Price to Earnings (P/E): 6.3
• Beta (1Y): 0.66
• Revenue Growth: 19.80%
• EPS Growth: 55.09%
• Country: HK
• Employees: 1,022
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.11
• Shares Outstanding: 588,835,300
• 10 Day Avg. Volume: 4,101,801
• 30 Day Avg. Volume: 5,400,283
• PEG Ratio: 0.02
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 0.60
• P/FCF Ratio: 24.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: HK$1.50 ▼(-3.23% Downside)
• Action: Reiterated Date: 11/22/25
• Date: Action: Reiterated 11/22/25

The overall stock score is primarily influenced by the company's solid financial performance and attractive valuation. However, the bearish technical indicators suggest caution in the short term. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Cash Generation

Sustained FCF growth of 24.27% TTM indicates improving cash conversion that supports durable needs: R&D funding, commercial scale-up, dividend or buybacks, and selective M&A. Strong FCF reduces reliance on external financing and improves resilience through cyclical downturns.

Balance Sheet Health

A conservative leverage profile (D/E 0.13) and equity ratio ~64.9% provide financial flexibility for multi-year drug development cycles. Low debt limits refinancing risk, preserves capacity to fund clinical programs or partnerships, and cushions the balance sheet in adverse conditions.

Margin Base & Portfolio Diversity

A stable gross margin above 50% suggests structurally favorable manufacturing economics and pricing across proprietary and generic lines. Combined with a product mix spanning oncology, cardiovascular and metabolic areas, this supports durable margin sustainability as sales scale and new products commercialize.

Negative Factors

Return on Equity

ROE around 5.4% signals limited returns on invested capital versus typical growth-stage biotech expectations. Persistently modest ROE can reflect slow commercialization traction, suboptimal pricing or capital allocation, constraining long-term shareholder value creation absent operational improvement.

Operational Efficiency

An EBIT margin near 9.3% indicates limited operating leverage and potential inefficiencies in R&D or SG&A. For a pharmaceutical firm, low EBIT constrains reinvestment capacity and weakens profitability resilience, making sustained margin expansion critical for long-term cash generation and competitiveness.

Investor Communication / Visibility

Absence of earnings call commentary and limited corporate event disclosure reduces transparency around pipeline progress, commercialization plans and guidance. Over a multi-month horizon, this hampers investors' ability to assess execution risk and management priorities for long-term value realization.

Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company Description

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

How the Company Makes Money

Lee's Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include both proprietary drugs and generic medications. The company has a diversified revenue model that includes direct sales to healthcare providers and institutions, as well as partnerships with other pharmaceutical companies for co-development and distribution of products. Key revenue streams also come from licensing agreements, where Lee's licenses its drug candidates to other firms for further development and commercialization, leading to milestone payments and royalties. Additionally, the company benefits from strategic collaborations and partnerships, which enhance its product pipeline and market reach, contributing significantly to its overall earnings.

Lee's Pharmaceutical Holdings Limited Financial Statement Overview

Summary

Lee's Pharmaceutical Holdings Limited demonstrates a solid financial position with stable revenue growth and strong cash flow generation. The balance sheet reflects low leverage and a strong equity base, while profitability metrics indicate potential for operational improvements.

Income Statement

The company shows a positive revenue growth rate of 1.29% TTM, indicating a recovery from previous declines. Gross profit margin remains stable at 53.10%, while net profit margin has improved to 6.81% TTM. However, the EBIT margin is relatively low at 9.25%, suggesting room for operational efficiency improvements.

Balance Sheet

The debt-to-equity ratio is low at 0.13, reflecting a conservative leverage approach. Return on equity is modest at 5.44% TTM, indicating moderate profitability. The equity ratio stands at 64.86%, showcasing a strong equity position relative to assets.

Cash Flow

The company exhibits strong free cash flow growth of 24.27% TTM, indicating improved cash generation. The operating cash flow to net income ratio is 0.45, suggesting efficient cash conversion. Free cash flow to net income ratio is high at 0.88, highlighting robust cash flow relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44B	1.40B	1.05B	1.23B	1.27B	1.22B
Gross Profit	762.81M	753.36M	551.31M	770.75M	806.28M	781.07M
EBITDA	263.90M	260.87M	193.05M	229.06M	2.13B	279.43M
Net Income	97.81M	93.10M	16.70M	51.28M	1.99B	129.32M
Balance Sheet
Total Assets	3.00B	2.62B	2.89B	2.78B	3.64B	3.25B
Cash, Cash Equivalents and Short-Term Investments	303.58M	216.84M	171.00M	189.30M	277.53M	414.54M
Total Debt	243.63M	227.30M	204.14M	163.49M	267.14M	156.71M
Total Liabilities	1.17B	1.07B	930.07M	939.50M	1.25B	1.14B
Stockholders Equity	1.94B	1.65B	2.04B	1.92B	2.46B	2.15B
Cash Flow
Free Cash Flow	324.98M	34.45M	-49.63M	69.81M	-160.04M	-139.23M
Operating Cash Flow	367.35M	242.01M	110.08M	283.63M	210.68M	218.91M
Investing Cash Flow	-211.36M	-190.23M	-145.22M	-256.05M	-370.28M	-523.74M
Financing Cash Flow	-35.65M	-1.96M	13.44M	-128.60M	60.97M	-9.80M

Lee's Pharmaceutical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.46, above the 50-day MA of 1.54, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 25.34 is Positive, neither overbought nor oversold. The STOCH value of 7.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0950.

Lee's Pharmaceutical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	HK$6.90B	2.21	10.85%	5.80%	-20.64%	-25.39%
2348	72 Outperform	HK$1.76B	4.06	5.34%	5.16%	2.89%	-68.83%
0950	64 Neutral	HK$783.15M	6.31	5.35%	2.92%	19.80%	55.09%
0719	58 Neutral	HK$9.87B	35.32	7.48%	4.47%	1.65%	-16.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	50 Neutral	HK$12.60B	22.81	-1.87%	0.87%	19.21%	-115.91%

Lee's Pharmaceutical Holdings Limited Corporate Events

Lee’s Pharm Wins FDA Clearance for U.S. ADASUVE Manufacturing Shift

Lee’s Pharmaceutical Holdings Limited has secured U.S. Food and Drug Administration approval for a supplemental new drug application relating to ADASUVE (loxapine) Inhalation Powder, authorising the move of the drug’s commercial manufacturing facility from Mountain View to Fremont, California. The approval, obtained via its wholly owned U.S. subsidiary Nova Pneuma Incorporated following the acquisition of the relevant assets in December 2025, clears the Fremont site for commercial production of ADASUVE in the United States and marks completion of the regulatory requirements tied to Lee’s Pharm’s first U.S.-based pharmaceutical facility acquisition. This milestone strengthens the group’s push into innovative drug delivery technologies based on the Staccato platform, underpins its global expansion strategy, and reinforces its emphasis on regulatory compliance and pharmaceutical quality, with implications for an enhanced U.S. footprint and broader therapeutic applications over time.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.

Lee’s Pharma Adds Financial Detail to Discloseable Asset Acquisition

Lee’s Pharmaceutical Holdings Limited has issued a supplemental announcement regarding its previously disclosed acquisition of certain assets, providing additional financial details on the purchased portfolio. The company reported that the acquired assets generated revenue of US$4.584 million and gross profit of US$3.997 million in 2023, and revenue of US$3.217 million and gross profit of US$511,000 in 2024, based on the seller’s audited financial statements. Management noted it is impracticable to determine net profit or loss attributable to the assets because certain expenses relate to excluded items not forming part of the acquisition, but emphasized that this additional disclosure does not alter other terms or information previously announced about the transaction, offering investors more clarity on the historical performance of the acquired business components.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.

Lee’s Pharmaceutical Mourns Death of Senior Business Development Director Michele Dalla Libera

Lee’s Pharmaceutical Holdings Limited has announced the death of Michele Dalla Libera, its Senior Director of Business Development, on 15 December 2025. Dalla Libera was instrumental in the group’s evolution after its 2002 listing, leading the in-licensing of key drug products from European partners and helping transform the company from a small biopharmaceutical player into a stronger organisation with a stable revenue foundation. The board expressed deep sorrow and extended condolences to his family, highlighting his leadership, professionalism and commitment to improving patients’ lives as enduring influences on the company’s mission and future development.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.

Lee’s Pharmaceutical Acquires Alexza Business Assets for $15 Million

Lee’s Pharmaceutical Holdings Limited has announced a significant acquisition involving the purchase of assets related to the Alexza Business for US$15 million. This transaction, which involves intellectual property rights, inventories, and equipment, is classified as a discloseable transaction under Hong Kong’s Listing Rules, indicating its substantial impact on the company’s operations and market positioning.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.